<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003548</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066605</org_study_id>
    <secondary_id>U01CA076642</secondary_id>
    <secondary_id>P30CA016087</secondary_id>
    <secondary_id>NYU-9753</secondary_id>
    <secondary_id>NCI-T97-0123</secondary_id>
    <nct_id>NCT00003548</nct_id>
  </id_info>
  <brief_title>Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity</brief_title>
  <official_title>Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients
      with advanced cancer of the peritoneal cavity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the qualitative and quantitative toxicities of intraperitoneal
      aminocamptothecin colloidal dispersion administered every 28 days in 6 applications over a 12
      day period in patients with advanced cancer confined to the peritoneal cavity. II. Determine
      the maximum tolerated dose of aminocamptothecin colloidal dispersion on this novel schedule
      in this patient population. III. Obtain pharmacological and biochemical data as potential
      predictors of responses and/or drug toxicities in these patients. IV. Document the presence
      and degree of antitumor activity of this regimen in this patient population.

      OUTLINE: This is a dose escalation study. Patients receive intraperitoneal aminocamptothecin
      colloidal dispersion (9-AC) over 30-60 minutes in 6 applications over a 12 day period (days
      1, 3, 5, 8, 10, and 12). Courses are repeated every 28 days. Treatment continues for 4-6
      courses in the absence of unacceptable toxic effects or disease progression. The dose of 9-AC
      is escalated in cohorts of 3-6 patients until the maximum tolerated dose (MTD) is determined.
      The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience
      dose limiting toxicity. Patients are followed until death.

      PROJECTED ACCRUAL: Approximately 15-20 patients will be accrued for this study within 18
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminocamptothecin colloidal dispersion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed advanced malignancy involving the
        peritoneal cavity, excluding leukemia and lymphoma Patients with ovarian cancer must have
        received prior standard therapy Predominantly small tumor metastases less than 1.0 cm in
        diameter including: Ovarian cancer with epithelial histology Other gynecological tumors
        Breast cancer Gastric cancer Colorectal cancer Appendiceal cancer Pancreatic cancer Unknown
        primary cancer Other malignancies with predominantly intraperitoneal manifestation No
        extensive intraperitoneal adhesions that cannot be easily lysed laparoscopically or by
        laparotomy No symptomatic disease outside the peritoneal cavity Asymptomatic disease
        outside the peritoneum considered (e.g., bone lesions)

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL AST no greater than 2 times upper
        limit of normal Renal: Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and/or
        mitomycin) Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior
        radiotherapy Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco M. Muggia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>February 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2004</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV anal cancer</keyword>
  <keyword>recurrent anal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage IV cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage IV vulvar cancer</keyword>
  <keyword>recurrent vulvar cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>stage IVB vaginal cancer</keyword>
  <keyword>recurrent vaginal cancer</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent gestational trophoblastic tumor</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

